Harmony Biosciences Holdings (HRMY) Interest & Investment Income (2023 - 2026)
Harmony Biosciences Holdings (HRMY) reported Interest & Investment Income of $5.8 million for Q1 2026, up 14.14% on a YoY basis from $5.0 million in Q1 2025, and down 1.66% sequentially from $5.9 million in Q4 2025.
Harmony Biosciences Holdings (HRMY) Interest & Investment Income (2023 - 2026) Analysis & Trends
Harmony Biosciences Holdings (HRMY) has 4 years of Interest & Investment Income data on file, last reported at $5.8 million in Q1 2026.
- For the quarter ending Q1 2026, Interest & Investment Income rose 14.14% year-over-year to $5.8 million; the trailing twelve-month figure through Mar 2026 stood at $22.6 million (up 18.16% YoY), and the FY2025 full-year result was $21.9 million, up 18.24% from the prior year.
- Interest & Investment Income fell to $5.8 million in Q1 2026, from $5.9 million in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $5.9 million in Q4 2025 to a low of $3.1 million in Q1 2023.
- A 4-year average of $4.7 million and a median of $4.7 million in 2024 frame the typical range for Interest & Investment Income.
- Peak annual rise in Interest & Investment Income reached 43.49% in 2024, while the deepest fall reached 9.3% in 2024.
- Tracing HRMY's Interest & Investment Income over 4 years: stood at $4.1 million in 2023, then rose by 9.3% to $4.5 million in 2024, then soared by 30.76% to $5.9 million in 2025, then fell by 1.66% to $5.8 million in 2026.
- Business Quant data shows HRMY's Interest & Investment Income at $5.8 million in Q1 2026, $5.9 million in Q4 2025, and $5.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Nanobiotix | 1,792.52 Bn | 1,792.46 Bn | - | - |
| 2 | Akari Therapeutics | 999.95 Bn | 999.95 Bn | - | - |
| 3 | BeOne Medicines | 475.97 Bn | 471.17 Bn | 1.35 Bn | 27.66 Mn |
| 4 | Vertex Pharmaceuticals | 124.91 Bn | 117.66 Bn | 2.59 Bn | 114.80 Mn |
| 5 | Regeneron Pharmaceuticals | 72.31 Bn | 63.56 Bn | 3.31 Bn | -65.80 Mn |
| 6 | Belite Bio | 62.01 Bn | 62.01 Bn | - | - |
| 7 | Argenx Se | 54.23 Bn | 49.04 Bn | 1.41 Bn | 48.00 Mn |
| 8 | Alnylam Pharmaceuticals | 38.31 Bn | 35.30 Bn | 959.66 Mn | 26.60 Mn |
| 9 | Revolution Medicines | 36.16 Bn | 36.16 Bn | - | 19.51 Mn |
| 10 | Harmony Biosciences Holdings | 2.06 Bn | 1.54 Bn | 170.88 Mn | 5.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.76 Mn |
| Dec 31, 2025 | 5.85 Mn |
| Sep 30, 2025 | 5.73 Mn |
| Jun 30, 2025 | 5.30 Mn |
| Mar 31, 2025 | 5.04 Mn |
| Dec 31, 2024 | 4.48 Mn |
| Sep 30, 2024 | 4.93 Mn |
| Jun 30, 2024 | 4.71 Mn |
| Mar 31, 2024 | 4.43 Mn |
| Dec 31, 2023 | 4.10 Mn |
| Sep 30, 2023 | 4.11 Mn |
| Jun 30, 2023 | 3.44 Mn |
| Mar 31, 2023 | 3.09 Mn |